|
|
| Research article summary (published 29 Sep 2009): |
Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes.
Full Abstract
OBJECTIVE: To report a case of leukocytoclastic vasculitis associated with insulin aspart therapy. CASE SUMMARY: A 56-year-old man was admitted to the Department of Endocrinology because of a poorly controlled Type 2 diabetes. In an attempt to reach a tight blood glucose control, an intensive diabetes management consisting of one evening dose of intermediate-acting NPH insulin and three preprandial doses of short-acting insulin aspart was introduced. Two weeks following insulin aspart introduction the patient developed palpable purpura on distal parts of the upper and lower limbs. Four days after the onset of purpura, a skin biopsy was preformed. Histological examination showed vasculitis with perivascular infiltrates of lymphocytes and erythrocyte extravasation. Direct immunofluorescence was negative. On the day the purpuric eruptions appeared, insulin aspart was substituted with regular human insulin. All skin lesions disappeared spontaneously within 8 days. Insulin aspart was not re-administered. DISCUSSION: Other possible causes of vasculitis in this case were excluded by diagnostic tests. The temporal relationship between the insulin aspart administration and the occurrence of purpura, with no further episodes of skin eruptions after discontinuation of the drug, support the hypothesis of an insulin aspart caused vasculitis. Based on the Naranjo's algorithm, the adverse drug reaction could be considered possible. CONCLUSION: Clinicians should be aware of the possibility of leukocytoclastic vasculitis occurring during insulin aspart treatment.
Author information
Author/s: Marusic, S (S); Vlahovic-Palcevski, V (V); Ljubanovic, D (D);
Affiliation: Department of Clinical Pharmacology, University Hospital Dubrava, Zagreb, Croatia. srmarusic(-atsign-)inet.hr
Journal and publication information
Publication Type: Case Reports; Journal Article
Journal: International journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther), published in Germany. (Language: eng)
Reference: 2009-Oct; vol 47 (issue 10) : pp 603-5
Dates: Created 2009/10/14; Completed 2009/11/05;
PMID: 19825323, status: MEDLINE (last retrieval date: 11/5/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study.
28 Feb 2008 - Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.
30 Dec 2006 - At last, a weight neutral insulin?
30 Aug 2004 - Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
24 Jan 2007 - [Insulin analogs and new antidiabetic agents. Prospects in diabetes therapy]
30 May 1997 - Study design and baseline characteristics of patients in the PRESENT study.
28 Jul 2008 - Impact of therapeutic advances on hypoglycaemia in type 2 diabetes.
29 Apr 2008 - Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
30 Jan 2008 - [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin]
30 Dec 2003 - Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
29 Apr 2002
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.